--- schema_version: "secwatch.filing_event.v1" accession: "0000950170-25-014630" form_type: "8-K" ticker: null cik: "0001061027" company_name: "Viracta Therapeutics, Inc." filed_at: "2025-02-05T23:59:59+00:00" generated_at: "2026-05-27T02:20:07.046915+00:00" event_type: "other_material" sentiment: "negative" materiality_score: 1.0 calibrated_materiality_score: 1.0 confidence: "high" source: SEC EDGAR --- # Viracta Therapeutics terminates employees, wind down operations; all directors resign ## Summary - Board approved workforce reduction effective Feb 5, 2025; expects ~$0.1M in severance and related costs. - All directors (Pomerantz, Borellini, Darcy, Royston, Rothera) resigned; CEO Rothera, CFO Faerm, CMO Cohen cease officer roles. - Craig Jalbert appointed sole director, CEO, President, CFO, Treasurer and Corporate Secretary; compensated $50K/yr for 3 years. - Company exploring strategic alternatives for its virus-associated cancer development programs. - Wind down follows clinical-stage operations; stock ticker VIRX. ## SEC filing metadata - accession: 0000950170-25-014630 - form_type: 8-K - cik: 0001061027 - company_name: Viracta Therapeutics, Inc. - filed_at: 2025-02-05T23:59:59+00:00 - event_type: other_material - sentiment: negative - materiality_score: 1.0 - calibrated_materiality_score: 1.0 - confidence: high - sec_items: 2.05, 5.02, 8.01, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1061027/000095017025014630/0000950170-25-014630-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1061027/000095017025014630/virx-20250203.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0000950170-25-014630 - JSON: https://secwatch.observer/filing/0000950170-25-014630.json - Plain text: https://secwatch.observer/filing/0000950170-25-014630.txt ## Key facts - Executive change Mark Rothera departed as President and Chief Executive Officer at Viracta Therapeutics, Inc.. - Action: ceased serving - Role: President and Chief Executive Officer source text: it was determined that each of Mark Rothera, President and Chief Executive Officer, Michael Faerm, Chief Financial Officer, and Darrel P. Cohen M.D., Ph.D., Chief Medical Officer, would cease serving in their respective officer positions as of the Effective Time. evidence_url: https://www.sec.gov/Archives/edgar/data/1061027/000095017025014630/0000950170-25-014630-index.htm - Executive change Craig R. Jalbert was appointed as Director at Viracta Therapeutics, Inc.. - Action: appointed - Role: Director source text: the Board appointed Craig R. Jalbert, age 63, as the Company's Chief Executive Officer, President, Chief Financial Officer, Treasurer and Corporate Secretary, and sole member of the Board. evidence_url: https://www.sec.gov/Archives/edgar/data/1061027/000095017025014630/0000950170-25-014630-index.htm - Executive change Michael Faerm departed as Chief Financial Officer at Viracta Therapeutics, Inc.. - Action: ceased serving - Role: Chief Financial Officer source text: it was determined that each of Mark Rothera, President and Chief Executive Officer, Michael Faerm, Chief Financial Officer, and Darrel P. Cohen M.D., Ph.D., Chief Medical Officer, would cease serving in their respective officer positions as of the Effective Time. evidence_url: https://www.sec.gov/Archives/edgar/data/1061027/000095017025014630/0000950170-25-014630-index.htm - Executive change Roger Pomerantz resigned as Director at Viracta Therapeutics, Inc.. - Action: resigned - Role: Director source text: Roger Pomerantz, M.D., Flavia Borellini, Ph.D., Thomas E. Darcy, CPA, Ivor Royston, M.D., and Mark Rothera, representing all of the Company's current Board members, each notified the Company of their respective resignations as members of the Board evidence_url: https://www.sec.gov/Archives/edgar/data/1061027/000095017025014630/0000950170-25-014630-index.htm - Executive change Craig R. Jalbert was appointed as Chief Executive Officer, President, Chief Financial Officer, Treasurer and Corporate Secretary at Viracta Therapeutics, Inc.. - Action: appointed - Role: Chief Executive Officer, President, Chief Financial Officer, Treasurer and Corporate Secretary source text: the Board appointed Craig R. Jalbert, age 63, as the Company's Chief Executive Officer, President, Chief Financial Officer, Treasurer and Corporate Secretary, and sole member of the Board. evidence_url: https://www.sec.gov/Archives/edgar/data/1061027/000095017025014630/0000950170-25-014630-index.htm - Executive change Darrel P. Cohen departed as Chief Medical Officer at Viracta Therapeutics, Inc.. - Action: ceased serving - Role: Chief Medical Officer source text: it was determined that each of Mark Rothera, President and Chief Executive Officer, Michael Faerm, Chief Financial Officer, and Darrel P. Cohen M.D., Ph.D., Chief Medical Officer, would cease serving in their respective officer positions as of the Effective Time. evidence_url: https://www.sec.gov/Archives/edgar/data/1061027/000095017025014630/0000950170-25-014630-index.htm - Executive change Thomas E. Darcy resigned as Director at Viracta Therapeutics, Inc.. - Action: resigned - Role: Director source text: Roger Pomerantz, M.D., Flavia Borellini, Ph.D., Thomas E. Darcy, CPA, Ivor Royston, M.D., and Mark Rothera, representing all of the Company's current Board members, each notified the Company of their respective resignations as members of the Board evidence_url: https://www.sec.gov/Archives/edgar/data/1061027/000095017025014630/0000950170-25-014630-index.htm - Executive change Mark Rothera resigned as Director at Viracta Therapeutics, Inc.. - Action: resigned - Role: Director source text: Roger Pomerantz, M.D., Flavia Borellini, Ph.D., Thomas E. Darcy, CPA, Ivor Royston, M.D., and Mark Rothera, representing all of the Company's current Board members, each notified the Company of their respective resignations as members of the Board evidence_url: https://www.sec.gov/Archives/edgar/data/1061027/000095017025014630/0000950170-25-014630-index.htm - Executive change Ivor Royston resigned as Director at Viracta Therapeutics, Inc.. - Action: resigned - Role: Director source text: Roger Pomerantz, M.D., Flavia Borellini, Ph.D., Thomas E. Darcy, CPA, Ivor Royston, M.D., and Mark Rothera, representing all of the Company's current Board members, each notified the Company of their respective resignations as members of the Board evidence_url: https://www.sec.gov/Archives/edgar/data/1061027/000095017025014630/0000950170-25-014630-index.htm - Executive change Flavia Borellini resigned as Director at Viracta Therapeutics, Inc.. - Action: resigned - Role: Director source text: Roger Pomerantz, M.D., Flavia Borellini, Ph.D., Thomas E. Darcy, CPA, Ivor Royston, M.D., and Mark Rothera, representing all of the Company's current Board members, each notified the Company of their respective resignations as members of the Board evidence_url: https://www.sec.gov/Archives/edgar/data/1061027/000095017025014630/0000950170-25-014630-index.htm - Restructurings & Charges Viracta Therapeutics, Inc. announced a restructuring with charges of approximately $0.1 million. - Type: restructuring - Charge: approximately $0.1 million source text: The Company expects to incur one-time charges and cash expenditures associated with the workforce reduction of approximately $0.1 million, primarily related to employee wages and severance payments, benefits and related termination costs. evidence_url: https://www.sec.gov/Archives/edgar/data/1061027/000095017025014630/0000950170-25-014630-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.